Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up

导出原文传递

翻译打印收藏纠错

作者： Lin, Jian-Xian ^[1] ; Chen, Qing-Feng ; Zheng, Chao-Hui ; Li, Ping ; Xie, Jian-Wei ; Wang, Jia-Bin ; Lu, Jun ; Chen, Qi-Yue ; Cao, Long-Long ; Lin, Mi ; Tu, Ru-Hong ; Huang, Chang-Ming

作者单位： Fujian Med Univ, Dept Gastr Surg, Union Hosp, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China ^[1]

关键词 Gastrointestinal stromal tumors Imatinib mesylate Prognosis

发布时间 2018-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Journal of Cancer Research and Clinical Oncology

2017年143卷4期

727-734页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up

Journal of Cancer Research and Clinical Oncology

相似文献

Journal of Cancer Research and Clinical Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up

Journal of Cancer Research and Clinical Oncology

相似文献

Journal of Cancer Research and Clinical Oncology

相关期刊

检索历史清除